Chris Mason
Company: AvroBio
Job title: CSO
Bio:
Chris is a Founder and Chief Science Officer at AVROBIO, a clinical-stage, gene therapy company in Cambridge, Massachusetts. He is a clinician-scientist with over 25 years of cell and gene therapy experience including Full Professor of Cell and Gene Therapy in the Advanced Centre for Biochemical Engineering, University College London, UK. He has a multidisciplinary track record, spanning R&D, clinical practice, bioprocessing, regulation, healthcare economics, reimbursement and business. Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical translation and commercialization of cell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK-Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, and Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM). Chris is Senior Editor of the journals; ‘Cell and Gene Therapy Insights’ and ‘Regenerative Medicine’.
Seminars:
Chair’s Closing Remarks 5:00 pm
day: Day Two
Chair’s Opening Remarks 7:50 am
day: Day Two
Chair’s Closing Remarks 7:00 pm
day: Day One
Chair’s Opening Remarks 7:50 am
day: Day One